MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
42.59
-1.51
-3.42%
After Hours: 42.59 0 0.00% 17:32 05/15 EDT
OPEN
43.49
PREV CLOSE
44.10
HIGH
43.95
LOW
42.35
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
48.61
52 WEEK LOW
13.88
MARKET CAP
3.96B
P/E (TTM)
-159.7524
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)
TipRanks · 18h ago
XBI, APLS, TGTX, TVTX: Large Inflows Detected at ETF
NASDAQ · 1d ago
Travere Therapeutics grants inducement equity awards covering 48,800 shares to new hires
PUBT · 3d ago
TRAVERE THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
TipRanks · 4d ago
Travere Therapeutics plans offering of $400 million convertible senior notes due 2032
PUBT · 4d ago
Weekly Report: what happened at TVTX last week (0504-0508)?
Weekly Report · 4d ago
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.